Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

61. Short-term prognosis of hemodynamycally unstable patients with acute symptomatic pulmonary embolism: systematic review and meta-analysis

Short-term prognosis of hemodynamycally unstable patients with acute symptomatic pulmonary embolism: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

62. Preferred anticoagulants after thrombolysis for acute pulmonary embolism: a meta analysis

Preferred anticoagulants after thrombolysis for acute pulmonary embolism: a meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

63. Ruling out pulmonary embolism across different subgroups of patients and healthcare settings: protocol for a systematic review and individual patient data meta-analysis (IPDMA)

Ruling out pulmonary embolism across different subgroups of patients and healthcare settings: protocol for a systematic review and individual patient data meta-analysis (IPDMA) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

64. Prognostic value of right ventricular dysfunction and elevated cardiac biomarkers in patients with low-risk pulmonary embolism

Prognostic value of right ventricular dysfunction and elevated cardiac biomarkers in patients with low-risk pulmonary embolism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

65. Pulmonary embolism

Pulmonary embolism Pulmonary embolism - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Pulmonary embolism Last reviewed: February 2019 Last updated: July 2018 Summary Pulmonary embolism (PE) is a life-threatening condition resulting from dislodged thrombi occluding the pulmonary vasculature; right heart failure and cardiac arrest may ensue if not aggressively treated. Symptoms include chest pain, dyspnoea, and a sense (...) , and supportive care. For those at intermediate risk of a poor outcome, anticoagulation and ongoing monitoring is required and rescue re-perfusion should be considered. Ongoing anticoagulation therapy is indicated to reduce the risk of recurrent events or fatal PE. Definition Pulmonary embolism (PE) is a consequence of thrombus formation within a deep vein of the body, most frequently in the lower extremities. Thrombus formation in the venous system occurs as a result of venous stasis, trauma

2018 BMJ Best Practice

66. Systematic review and meta-analysis of outcomes in patients with pulmonary embolism

Systematic review and meta-analysis of outcomes in patients with pulmonary embolism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

67. Catheter-directed therapies for the treatment of massive and submassive acute pulmonary embolism [Cochrane protocol]

Catheter-directed therapies for the treatment of massive and submassive acute pulmonary embolism [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

68. Diagnosis of pulmonary embolism: a systematic review and meta-analysis of test accuracy

Diagnosis of pulmonary embolism: a systematic review and meta-analysis of test accuracy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

69. Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism

Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism | CADTH.ca Find the information you need Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Published on: March 1, 2018 Project Number: OP0528-000 Product Line: Research Type: Other Diagnostics Result type: Report Pulmonary embolism (PE) is a blockage of one of the arteries in the lung (...) as potential environmental impact were also addressed. Tags blood, decision support techniques, diagnostic tests, echocardiography, fibrin fibrinogen degradation products, magnetic resonance imaging, pet scan, perfusion imaging, positron-emission tomography, pulmonary embolism, radionuclide imaging, spect, tomography, ultrasonography, venous thromboembolism, ct scan, imaging, mri, respiratory, ultrasound, CT angiography, CT pulmonary angiography, CTPA, Emission-Computed, Geneva, MRIs, PERC, PET, PET-CT

2018 CADTH - Optimal Use

70. Clinical Value of Ultrasonography in Diagnosis of Pulmonary Embolism in Critically Ill Patients (PubMed)

Clinical Value of Ultrasonography in Diagnosis of Pulmonary Embolism in Critically Ill Patients Pulmonary embolism (PE) is a clinical emergency that will increase the mortality if complicated with unstable hemodynamics. Because of its nonspecific clinical symptoms, it's a great challenge to make a PE diagnosis. The golden standard to diagnose PE is computed tomography of pulmonary artery (CTPA), but a diagnosis of PE also composed of evaluation of PE risk factors, possibilities, and risk (...) stratification. Ultrasonography may detect right ventricle strain related to hemodynamic change, intravascular thrombosis, thrombosis in right heart or pulmonary arteries, pulmonary infarction, and local pleural effusion. Combination of ultrasound and traditional PE possibility evaluation score may further improve the pretest probability of CTPA. A comprehensive ultrasonography may sometimes rule out PE and may disclose other causes for the clinical situations. A heart-lung-vessel-integrated multiorgan

Full Text available with Trip Pro

2017 Journal of translational internal medicine

71. No added value of the age-adjusted D-dimer cut-off to the YEARS algorithm in patients with suspected pulmonary embolism

No added value of the age-adjusted D-dimer cut-off to the YEARS algorithm in patients with suspected pulmonary embolism Essentials Imaging is warranted in the majority of patients to confirm or rule out pulmonary embolism (PE). The age-adjusted D-dimer (ADJUST) reduced the number of required imaging tests in patients ≥ 50 years. The YEARS algorithm was designed to improve the efficiency in patients with suspected PE. There was no added value of implementing ADJUST in the YEARS algorithm in our (...) cohort.Background The YEARS algorithm was designed to simplify the diagnostic work-up of pulmonary embolism (PE) and to reduce the number of necessary computed tomography pulmonary angiography (CTPA) scans. An alternative strategy to reduce the number of CTPAs is the age-adjusted D-dimer cut-off (ADJUST) in patients aged 50 years or older. We aimed to investigate whether a combination of both diagnostic strategies might save additional CTPAs. Methods The YEARS algorithm consists of three items (clinical signs

Full Text available with Trip Pro

2017 EvidenceUpdates

72. Blood and Clots Quizlet 1: Oral Contraceptives and Pulmonary Embolism

Blood and Clots Quizlet 1: Oral Contraceptives and Pulmonary Embolism Blood and Clots Quizlet 1: Oral Contraceptives and Pulmonary Embolism - CanadiEM Blood and Clots Quizlet 1: Oral Contraceptives and Pulmonary Embolism In , by Eric Tseng October 27, 2017 Hello Blood & Clots/CanadiEM community! Before we post our blog series on thrombosis and bleeding, we encourage you to test your initial knowledge by going through a few brief case scenarios. These cases were originally posted as part of our (...) to someone who started COC only 3 months prior. In this situation her pre-test probability is driven not by her COC but her clinical presentation. Therefore, it is reasonable to perform a D-Dimer test to exclude pulmonary embolism as she is low pretest probability. This conservative approach may obviate the need for CT scan and avoid radiation exposure. Question 3: You discover that she has a family history of a hypercoagulable disorder. How does this change management? A) This is highly unlikely

2017 CandiEM

73. Approaches to Diagnosing Acute Pulmonary Embolism in Canada: current practice, challenges, and availability of testing

Approaches to Diagnosing Acute Pulmonary Embolism in Canada: current practice, challenges, and availability of testing Approaches to Diagnosing Acute Pulmonary Embolism in Canada: current practice, challenges, and availability of testing | CADTH.ca Find the information you need Approaches to Diagnosing Acute Pulmonary Embolism in Canada: current practice, challenges, and availability of testing Approaches to Diagnosing Acute Pulmonary Embolism in Canada: current practice, challenges (...) , and availability of testing Published on: September 8, 2017 Project Number: ES0307-000 Product Line: Result type: Report CADTH undertook an environmental scan to identify and summarize information regarding pulmonary embolism (PE) imaging in Canada. The scan described current practice, challenges, and enablers in diagnosing PE, and the availability of tests, scans, and tools for diagnosing PE. The key objectives of this environmental scan were as follows: Identify current practice related to diagnostic

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

74. Assessing clinical probability of pulmonary embolism: prospective validation of the simplified Geneva score

Assessing clinical probability of pulmonary embolism: prospective validation of the simplified Geneva score Essentials The simplified Geneva score allows easier pretest probability assessment of pulmonary embolism (PE). We prospectively validated this score in the ADJUST-PE management outcome study. The study shows that it is safe to manage patients with suspected PE according to this score. The simplified Geneva score is now ready for use in routine clinical practice.Background Pretest (...) probability assessment by a clinical prediction rule (CPR) is an important step in the management of patients with suspected pulmonary embolism (PE). A limitation to the use of CPRs is that their constitutive variables and corresponding number of points are difficult to memorize. A simplified version of the Geneva score (i.e. attributing one point to each variable) has been proposed but never been prospectively validated. Aims Prospective validation of the simplified Geneva score (SGS) and comparison

Full Text available with Trip Pro

2017 EvidenceUpdates

75. Pulmonary embolism prognostic factors and length of hospital stay: A cohort study

Pulmonary embolism prognostic factors and length of hospital stay: A cohort study Patients with pulmonary embolism (PE) are commonly admitted to hospital for their initial treatment. We aimed to assess the association of length of hospital stay with commonly available clinical variables and their combinations.A retrospective multicenter cohort study was conducted on consecutive PE patients admitted to eight Italian centers. Logistic regression analysis was performed to evaluate the association (...) between the length of hospital stay and the Pulmonary Embolism Severity Index (PESI) parameters, National Early Warning Score (NEWS) and other possible determinants.We enrolled 391 patients, with a median hospital stay of 10days (IQR 7-14). Among PESI parameters, only oxygen saturation <90% was significantly associated with length of hospital stay at univariable analysis (OR 1.99; 95% CI 1.3-3.2). At multivariable analysis, NEWS ≥5 was associated with prolonged hospitalization (OR 3.14; 95% CI 1.2-8.3

2017 EvidenceUpdates

76. Lixiana (edoxaban) - for the prevention of embolism in patients with nonvalvular atrial fibrillation OR treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE.

Lixiana (edoxaban) - for the prevention of embolism in patients with nonvalvular atrial fibrillation OR treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. Lixiana (edoxaban) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Lixiana (edoxaban) Conclusion Lixiana (edoxaban) is the fourth Non-vitamin K Oral Anticoagulant (NOAC) in Denmark after Eliques (apixaban), Xarelto (rivaroxaban) and Pradaxa (...) (dabigatran). Lixiana is indicated for the prevention of embolism in patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. For either indication, Lixiana is not inferior to warfarin when it comes to preventing embolism and has a statistically significantly lower occurrence of major bleeding. The lower risk of bleeding is particularly evident in comparisons

2017 Danish Pharmacotherapy Reviews

77. Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism

Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism The impact of residual pulmonary obstruction on the outcome of patients with pulmonary embolism is uncertain.We recruited 647 consecutive symptomatic patients with a first episode of pulmonary embolism, with or without concomitant deep venous thrombosis. They received conventional anticoagulation, were assessed for residual pulmonary obstruction through perfusion lung scanning after 6 months (...) of the 324 patients (10.5%) with residual pulmonary obstruction and in 15 out of the 323 patients (4.6%) without residual pulmonary obstruction, leading to an adjusted hazard ratio of 2.26 (95% CI 1.23-4.16).Residual pulmonary obstruction, as detected with perfusion lung scanning at 6 months after a first episode of pulmonary embolism, is an independent predictor of recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension.Copyright ©ERS 2017.

Full Text available with Trip Pro

2017 EvidenceUpdates

78. Derivation and Validation of a Novel Prediction Model to Identify Low-Risk Patients With Acute Pulmonary Embolism

Derivation and Validation of a Novel Prediction Model to Identify Low-Risk Patients With Acute Pulmonary Embolism Accurate identification of low-risk patients with acute pulmonary embolism (PE) who may be eligible for outpatient treatment or early discharge can have substantial cost-saving benefit. The purpose of this study was to derive and validate a prediction model to effectively identify patients with PE at low risk of short-term mortality, right ventricular dysfunction, and other nonfatal

2017 EvidenceUpdates

79. D-dimer Interval Likelihood Ratios for Pulmonary Embolism

D-dimer Interval Likelihood Ratios for Pulmonary Embolism The objective was to estimate D-dimer interval likelihood ratios (iLRs) for diagnosing pulmonary embolism (PE).The authors used pooled patient-level data from five PE diagnostic management studies to estimate iLRs for the eight D-dimer intervals with boundaries 250, 500, 750, 1,000, 1,500, 2,500, and 5,000 ng/mL. Logistic regression was used to fit the data so that an interval increase corresponds to increasing the likelihood ratio

Full Text available with Trip Pro

2017 EvidenceUpdates

80. CRACKCast E088 – Pulmonary Embolism & Deep Venous Thrombosis

CRACKCast E088 – Pulmonary Embolism & Deep Venous Thrombosis CRACKCast E088 - Pulmonary Embolism & Deep Venous Thrombosis - CanadiEM CRACKCast E088 – Pulmonary Embolism & Deep Venous Thrombosis In , by Adam Thomas June 29, 2017 This episode of CRACKCast covers Rosen’s Chapter 88, DVT and PE. This episode covers the risk factors, diagnostic approach, treatment and management of PEs and DVTs. Shownotes – Rosen’s in Perspective This chapter is all about VTE – venous thromboembolism (...) discussion) Fondaparinux Apixaban Rivaroxaban OR heparin infusion after a loading bolus Ideally transition to oral anticoagulation at least 3 months (some up to 12 months) Encourage ambulation as much as possible Bedrest promotes DVT extension, risk of embolization, and post-DVT syndrome 8) What are the common causes of upper limb DVT? Upper limb DVT = thrombosis in the axillary vein “ The deep veins of the upper extremity include the paired ulnar, radial and interosseous veins in the forearm, paired

2017 CandiEM